Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trinity takes Capita herpes tests to the US:

This article was originally published in Clinica

Executive Summary

The US FDA has cleared for sale Trinity Biotech's ELISA tests for oral and genital herpes. The Capita herpes simplex virus (HSV) tests detect IgG antibodies to HSV 1 & 2 in serum and are among the first HSV type specific ELISAs to be cleared by the agency, according to the Dublin, Ireland company. They use recombinant glycoproteins that can accurately differentiate between antibodies to types 1 and 2 of the virus, and decrease or eliminate any potential cross reactivity. In the past HSV serological testing has been limited by the inability of assays to distinguish between antibodies to HSV-1 and HSV-2, the company claimed. HSV-1 is commonly associated with oral herpes and HSV-2 with genital herpes, although both have been shown to affect either area.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel